Genocea Biosciences
100 Acorn Park Drive
Cambridge
Massachusetts
02140
United States
Tel: 617-876-8191
Fax: 617-876-8192
Website: http://www.genocea.com/
Email: website.inquiry@genocea.com
About Genocea Biosciences
Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases.Genocea’s pipeline includes programs addressing genital herpes, pneumococcus, chlamydia, malaria and cancer immunotherapy. We currently have two products in Phase 2 clinical development:
• GEN-003, an immunotherapy to treat patients with genital herpes. We reported positive top-line data from an ongoing Phase 2b dose optimization trial from the immediate post dosing 28-day observation period in May 2015. We identified an improved dose of 60µg per protein/75µg of adjuvant, which demonstrated a highly statistically significant reduction (p>0.0001) from baseline in the viral shedding rate (55%) and genital lesion rate (60%). Data from the six-month and 12-month observation periods in this trial is expected in the fourth quarter of 2015 and the first quarter of 2016, respectively.
Data from the prior Phase 1/2a trial was the first time a therapeutic vaccine candidate has demonstrated significant reductions in the rates of viral shedding and genital lesions in genital herpes patients.
• GEN-004, a universal vaccine which is in Phase 2 development to prevent infections caused by all serotypes of pneumococcus. We have completed enrollment in a Phase 2 human challenge clinical trial and expect to report top-line data in the fourth quarter of 2015.
In a prior Phase 1 study, GEN-004 met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces.
193 articles with Genocea Biosciences
-
Genocea Provides Fourth Quarter 2019 Corporate Update
2/13/2020
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today reported its operating and financial results for the fourth quarter and fiscal year ended December 31, 2019.
-
Genocea to Host Fourth Quarter 2019 Corporate Update Conference Call & Webcast
2/6/2020
CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quarter 2019 financial results and corporate update conference call and live audio webcast on Thursday, February 13th at 8:30 a.m. EST. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID num
-
Genocea to Present at the Stifel 2019 Healthcare Conference
11/14/2019
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the Stifel 2019 Healthcare Conference on Wednesday, November 20th, at 1:15 pm Eastern Time.
-
Genocea Presents Preclinical Research that Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses at Society for Immunotherapy of Cancer (SITC)
11/5/2019
Proportions of inhibitory neoantigens found in cancer patients with the ATLAS™ biology-driven platform may also predict patient responses to immunotherapy
-
Genocea Provides Corporate Update and Reports Third Quarter 2019 Financial Results
10/24/2019
Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported its operating and financial results for the quarter ended September 30, 2019.
-
Genocea to Host Third Quarter 2019 Corporate Update Conference Call & Webcast
10/17/2019
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2019 financial results and corporate update conference call and live audio webcast on Thursday, October 24th at 8:30 a.m. EDT.
-
BioSpace Movers and Shakers: Dec. 17
12/17/2018
With the year closing out, biotech and pharma companies are making adjustments to their leadership ranks and boards of directors. -
GENOCEA APPOINTS GIRISH AAKALU, PH.D., CHIEF BUSINESS OFFICER
12/10/2018
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the hiring of industry veteran Girish Aakalu, Ph.D., as its new Chief Business Officer. I
-
Cofactor Genomics to Provide Solid Tumor Immune Profiling for Genocea Biosciences
12/4/2018
-- Pilot study to evaluate use of Cofactor assay in Genocea’s neoantigen vaccine clinical trial --
-
GENOCEA STRENGTHENS LEADERSHIP TEAM: THOMAS DAVIS, M.D. APPOINTED CHIEF MEDICAL OFFICER; DEREK MEISNER, J.D. JOINS AS GENERAL COUNSEL
10/1/2018
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced two additions to its leadership team: Thomas Davis, M.D. as Chief Medical Officer and Derek Meisner, J.D. as General Counsel.
-
Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results
2/15/2018
In January 2018, Genocea completed a $55 million equity financing, including significant investments from NEA and Vivo.
-
Genocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ET
2/8/2018
Genocea management will also provide an update on the Company's recent progress and upcoming milestones.
-
Genocea Biosciences Announces Proposed Concurrent Public Offerings of Common Stock and Class A Warrants and Series A Convertible Preferred Stock and Class A Warrants
1/17/2018
All the shares and warrants in the offerings are being offered by Genocea.
-
Genocea Biosciences Announces Pricing of $55M Concurrent Public Offerings
1/17/2018
The Class A warrants sold in each of the offerings will have the same terms.
-
Genocea Presents New Data Demonstrating the Power and Versatility of Its ATLAS Antigen Identification Platform at SITC 2017
11/7/2017
ATLAS continues to demonstrate superiority to in silico methods of neoantigen identification in multiple tumor types.
-
Genocea Reports Third Quarter 2017 Financial Results
11/2/2017
The company reported financial results for the third quarter of 2017 and announced upcoming data presentations at a leading immuno-oncology conference.
-
Genocea to Host Third Quarter 2017 Financial Results Conference Call & Webcast on November 2, 2017 at 9 a.m. ET
10/26/2017
Genocea management will also provide an update on the Company's recent progress and upcoming milestones.
-
Stock Plummets as Genocea Axes 40% of Jobs, Shifts R&D Focus in Restructuring
9/27/2017
-
Genocea Reports Second Quarter 2017 Financial Results
8/9/2017
-
Genocea Reports Positive Top-Line 12-Month Phase IIb Data For GEN-003 In Genital Herpes
7/24/2017